CytoDyn announces strong preclinical results using PRO 140 in human colon carcinoma
CytoDyn announces that PRO 140 (leronlimab) has been shown effective at inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The results were statistically significant and provide the basis for filing an IND application with the FDA for a clinical trial. August 15, 2018